Show simple item record

dc.contributor.authorOkyar, Alper
dc.contributor.authorLevi, Francis
dc.contributor.authorDulong, Sandrine
dc.contributor.authorInnominato, Pasquale F.
dc.contributor.authorClairambault, Jean
dc.date.accessioned2021-03-06T09:17:14Z
dc.date.available2021-03-06T09:17:14Z
dc.identifier.citationLevi F., Okyar A., Dulong S., Innominato P. F. , Clairambault J., "Circadian Timing in Cancer Treatments", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, cilt.50, ss.377-421, 2010
dc.identifier.issn0362-1642
dc.identifier.otherav_e4deaa16-a35d-4139-b94d-13d9ff124045
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/150597
dc.identifier.urihttps://doi.org/10.1146/annurev.pharmtox.48.113006.094626
dc.description.abstractThe circadian timing system is composed of molecular clocks, which drive 24-h changes in xenobiotic metabolism and detoxification, cell cycle events, DNA repair, apoptosis, and angiogenesis. The cellular circadian clocks are coordinated by endogenous physiological rhythms, so that they tick in synchrony in the host tissues that can be damaged by anticancer agents. As a result, circadian timing can modify 2- to 10-fold the tolerability of anticancer medications in experimental models and in cancer patients. Improved efficacy is also seen when drugs are given near their respective times of best tolerability, due to (a) inherently poor circadian entrainment of tumors and (b) persistent circadian entrainment of healthy tissues. Conversely, host clocks are disrupted whenever anticancer drugs are administered at their most toxic time. On the other hind, circadian disruption accelerates experimental and clinical cancer processes. Gender, circadian physiology, clock genes, and cell cycle critically affect outcome on cancer chronotherapeutics. Mathematical and systems biology approaches currently develop and integrate theoretical, experimental, and technological tools in order to further optimize and personalize the circadian administration of cancer treatments.
dc.language.isoeng
dc.subjectMeslek Bilimleri
dc.subjectTemel Eczacılık Bilimleri
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri
dc.subjectFarmasötik Toksikoloji
dc.subjectEczacılık
dc.subjectSağlık Bilimleri
dc.subjectTOKSİKOLOJİ
dc.subjectYaşam Bilimleri (LIFE)
dc.titleCircadian Timing in Cancer Treatments
dc.typeMakale
dc.relation.journalANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
dc.contributor.departmentAssistance Publique Hopitaux Paris (APHP) , ,
dc.identifier.volume50
dc.identifier.startpage377
dc.identifier.endpage421
dc.contributor.firstauthorID70395


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record